The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.

Related Insights

Wet lab experiments are slow and expensive, forcing scientists to pursue safer, incremental hypotheses. AI models can computationally test riskier, 'home run' ideas before committing lab resources. This de-risking makes scientists less hesitant to explore breakthrough concepts that could accelerate the field.

The era of advancing AI simply by scaling pre-training is ending due to data limits. The field is re-entering a research-heavy phase focused on novel, more efficient training paradigms beyond just adding more compute to existing recipes. The bottleneck is shifting from resources back to ideas.

CZI’s mission to cure all diseases is seen as unambitious by AI experts but overly ambitious by biologists. This productive tension forces biologists to pinpoint concrete obstacles and AI experts to grasp data complexity, accelerating the overall pace of innovation.

The future of valuable AI lies not in models trained on the abundant public internet, but in those built on scarce, proprietary data. For fields like robotics and biology, this data doesn't exist to be scraped; it must be actively created, making the data generation process itself the key competitive moat.

CZI focuses on creating new tools for science, a 10-15 year process that's often underfunded. Instead of just giving grants, they build and operate their own institutes, physically co-locating scientists and engineers to accelerate breakthroughs in areas traditional funding misses.

A key value of AI agents is rediscovering "lost" institutional knowledge. By analyzing historical experimental data, agents can prevent redundant work. For example, an agent found a previous study on mouse models that saved a company eight months and significant cost, surfacing data from an acquired company where the original scientists were gone.

A key strategy for labs like Anthropic is automating AI research itself. By building models that can perform the tasks of AI researchers, they aim to create a feedback loop that dramatically accelerates the pace of innovation.

Afeyan proposes that AI's emergence forces us to broaden our definition of intelligence beyond humans. By viewing nature—from cells to ecosystems—as intelligent systems capable of adaptation and anticipation, we can move beyond reductionist biology to unlock profound new understandings of disease.

Dr. Fei-Fei Li realized AI was stagnating not from flawed algorithms, but a missed scientific hypothesis. The breakthrough insight behind ImageNet was that creating a massive, high-quality dataset was the fundamental problem to solve, shifting the paradigm from being model-centric to data-centric.

The future of biotech moves beyond single drugs. It lies in integrated systems where the 'platform is the product.' This model combines diagnostics, AI, and manufacturing to deliver personalized therapies like cancer vaccines. It breaks the traditional drug development paradigm by creating a generative, pan-indication capability rather than a single molecule.

Top Biotech Labs Now Design Experiments to Train AI, Not Just Answer Questions | RiffOn